AC Immune's Alzheimer's vaccine generates potent anti-pTau Antibody response

12 February 2021
ac-immune-large

Shares of AC Immune (Nasdaq: ACIU) rose nearly 50% yesterday, and were up a further 15% at $8.43 pre-market today, after the Swiss biotech released positive data for its investigational Alzheimer’s vaccine.

AC Immune announced positive interim results from its ongoing Phase Ib/IIa clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease (AD). ACI-35.030 vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD, achieving antibody levels several orders of magnitude higher than pre-vaccination levels. No clinically relevant adverse events were observed.

AC Immune and strategic partner Janssen Pharmaceuticals, a unit of US healthcare giant Johnson & Johnson (NYSE: JNJ), believe these interim findings from the first two dosing groups support plans to advance the development of ACI-35.030 for the treatment of AD.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology